Sushil Suri
#983Chairman & Managing Director
61
Age
33y
Exp
33y
Tenure
6/10
Risk
🎓 MBBS · GSVM Medical College, Kanpur
📜 M.D. (Medicine) · GSVM Medical College, Kanpur
🏛️ None
CompensationTBP
Personality
6
Open
6
Cons
6
Extr
5
Agre
4
Neur
Morepen Labs.
Healthcare · Small Cap
High Growth · Performance-Driven
About
Sushil Suri is the Chairman & Managing Director of Morepen Labs., a Small Cap company in the Healthcare sector with a market cap of ₹2K Cr. A Transformational leader with 33 years of experience, he is known for authority-driven decision-making and organic builder strategy. Focuses on transitioning from legacy manufacturing to point-of-care diagnostics and branded generics.
FAQ
What is Sushil Suri's leadership style?
Sushil Suri is classified as a Transformational leader. He is authority-driven in decision-making, with a empire expander motivation and startup-speed pace of execution.
What is Sushil Suri's educational background?
Sushil Suri holds a MBBS from GSVM Medical College, Kanpur and a M.D. (Medicine) from GSVM Medical College, Kanpur.
Who is the CEO of Morepen Labs.?
Sushil Suri is the Chairman & Managing Director of Morepen Labs.. He has been with the company for 33 years and in the current role for 33 years.
Leadership DNA
ArchetypeTransformational
MotivationEmpire Expander
CrisisAggressive Pivoter
DecisionAuthority-Driven
GrowthOrganic Builder
PeopleInstitution Builder
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandValue-Champion
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Focuses on transitioning from legacy manufacturing to point-of-care diagnostics and branded generics.”
⚡ Crisis●●●●○
Successfully pivoted Morepen from a generic player to a focus on niche APIs and point-of-care diagnostics during market shifts.
🎯 Motivation●●●●○
Consistently focused on expanding the company's product portfolio and global footprint across diverse healthcare segments.
👥 People●●●○○
Focused on professionalizing operations and building long-term manufacturing capabilities and quality compliance systems.
📈 Growth●●●●○
Primarily focused on internal R&D and manufacturing capacity expansion rather than large-scale M&A.
💡 Innovation●●●●○
The company focuses on scaling generic drug manufacturing and niche API segments by entering established markets with cost-efficient, high-quality alternatives.
🏃 Pace●●●○○
The company has aggressively pivoted into new high-growth segments like medical devices and point-of-care diagnostics, showing an agile, rapid-expansion operational tempo.
🌱 Purpose●●●○○
The company operates primarily as a commercial pharmaceutical manufacturer with CSR activities focused on statutory compliance rather than integrated ESG-led social mission.
🏷️ Brand●●●●○
Morepen Labs positions itself as a provider of affordable, high-quality healthcare solutions, focusing on cost-leadership in the generic and API markets.
🤝 Customer●●●●○
A significant portion of revenue is derived from the supply of Active Pharmaceutical Ingredients (APIs) and finished dosages to other pharmaceutical companies and institutional distributors.
💼 Employer●●●○○
As a promoter-led, performance-driven small-cap, the culture emphasizes aggressive sales targets and operational efficiency to maintain competitive market positioning.
📋 Mandate
Transitioning from generic manufacturing to high-margin specialty products and R&D-driven growth requires a significant pivot in core business strategy.
🏢 Culture●●●○○
Aggressive market expansion in high-growth segments requires a results-oriented management style.
Financials
Revenue FY25₹2K Cr
PAT FY25₹118 Cr
Rev CAGR 5Y5.4%
OPM8%
NPM6.5%
ROE10.2%
ROCE11.4%
P/E21.2
Fwd P/E—
P/B1.8
D/E13.2
Promoter42.7%
Institutional1.4%
Mkt Cap₹2K Cr
Compensation
To Be Published
Data being verified from audited reports
